1. Psychedelic medicine: safety and ethical concerns;Anderson;Lancet Psychiatr.,2020
2. FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials;Assocation of Psychedelic Studies,2017
3. FDA intensifies drive to reduce REMS burdens: the key objective is to ease workflow obstacles for pharmacists;Barlas;Pharmacy and Therapeutics,2016
4. Psychedelics: where we are now, why we got here, what we must do;Belouin;Neuropharmacology,2018
5. Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research;Bender;Psychopharmacology,2022